Clinical aspects of CMV infection after stem cell transplantation.
Cytomegalovirus (CMV) infection is one of the most important infectious complications after stem cell transplantation (SCT). Major improvements in the management of CMV infection have been achieved during the last decade, including the introduction of safe blood product support for CMV-seronegative patients, the development of early pre-emptive antiviral therapy based on sensitive diagnostic tests, and antiviral prophylaxis. With the better control of CMV infection during the first 100 days after allogeneic SCT an increase in the incidence of CMV infection and disease after day 100 after transplantation was observed. New methods that allow for the reconstitution of CMV-specific immune responses such as adoptive T-cell therapy are promising tools that might help to improve the management of late CMV infection and disease.
Hebart
Holger
H
Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany. hrhebart@med.uni-tuebingen.de
Einsele
Hermann
H
D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D004279:DNA, Viral / Q000032:analysis; D006801:Humans; D008212:Lymphocyte Depletion; D012367:RNA, Viral / Q000032:analysis; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013997:Time Factors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral; D012367:RNA, Viral